iTeos Therapeutics to Present Inupadenant Data at ESMO Immuno-Oncology Congress
WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 – iTeos Therapeutics, Inc., a company at the forefront of developing innovative immuno-oncology therapeutics, has announced that it will present preclinical, translational, and clinical data on its drug candidate inupadenant at the upcoming European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024. This event is set to take place from December 11-13, 2024, in Geneva, Switzerland.
Inupadenant, known scientifically as EOS-850, is an advanced small molecule antagonist specifically targeting the adenosine A2A receptor (A2AR). This receptor, found on immune cells, is responsible for suppressing both innate and adaptive immune responses when activated by adenosine, ultimately inhibiting antitumor activities. Inupadenant has been optimized for high potency and selectivity towards A2AR, and it is designed to maintain its efficacy even in the presence of high adenosine concentrations commonly found in solid tumors. This optimization is thought to enhance its antitumor effectiveness compared to other A2AR antagonists currently in development.
The clinical data to be presented includes findings from the dose escalation stage of A2A-005, a Phase 2 trial assessing the efficacy of inupadenant combined with platinum-doublet chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) who have previously undergone immunotherapy. These results will be shared through mini oral presentations at the congress.
The details of the mini oral presentations are as follows:
- Title: "The A2AR Antagonist Inupadenant Promotes Humoral Responses in Patients"
Abstract Number: 174MO
Session Title: Mini Oral Session 1
Date/Time: December 12, 2024, at 9:24 am CEST
- Title: "Inupadenant Combined with Chemotherapy in Patients with Non-Squamous NSCLC Progressing On or After Immune Checkpoint Inhibitor Therapy: Results from Dose-Finding Part of the A2A-005 Trial"
Abstract Number: 120MO
Session Title: Mini Oral Session 2
Date/Time: December 12, 2024, at 14:55 pm CEST
In addition to the mini oral presentations, preclinical data on inupadenant will be presented during the poster session:
- Title: "The A2AR Antagonist Inupadenant Promotes Humoral Responses in Preclinical Models"
Abstract Number: 48P
Session Title: Poster Display Session
Date/Time: December 12, 2024, at 12:30 pm CEST
All regular abstracts from the ESMO-IO Congress 2024 will be published on the ESMO-IO website on December 5, 2024.
iTeos Therapeutics is based in Watertown, Massachusetts, and has a research center in Gosselies, Belgium. The company is dedicated to developing a new generation of immuno-oncology treatments. Its pipeline includes several clinical-stage programs that target immunosuppressive pathways with innovative pharmacological properties aimed at improving clinical outcomes. Among these programs are developments targeting the TIGIT/CD226 axis and the adenosine pathway.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
